COMPASS Pathways Plc (CMPS) - 10-K Summary
Business Context and Reporting Period
Company: COMPASS Pathways Plc
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A clinical-stage biotechnology company developing COMP360, a proprietary psilocybin formulation, primarily for Treatment-Resistant Depression (TRD) and Post-Traumatic Stress Disorder (PTSD). The company has no approved products and has not generated product revenue to date.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(287.9) million | $(155.1) million |
| Operating Expenses | $179.0 million | $178.2 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $149.6 million | $165.1 million |
| Accumulated Deficit | $(822.6) million | $(534.7) million |
| Debt (Carrying Value) | $31.6 million | $30.2 million |
Note: The 2025 Net Loss includes a non-cash fair value change of warrant liabilities of $(122.6) million.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $132.8 million year-over-year. This was primarily driven by a $122.6 million non-cash loss from the fair value change of warrant liabilities issued in the January 2025 financing.
- Operating Expenses: Total operating expenses remained relatively flat ($179.0M vs $178.2M). Research and Development (R&D) expenses decreased slightly ($118.4M vs $119.0M) due to reduced personnel and share-based compensation following a Q4 2024 reorganization, offset by increased development costs for late-stage trials. General and Administrative (G&A) expenses increased slightly ($60.6M vs $59.2M) due to higher legal and professional fees related to financing activities.
- Warrant Liabilities: A significant new line item appeared in 2025 due to the classification of Pre-funded Warrants and 2025 ADS Warrants as liabilities, resulting in the aforementioned fair value adjustment.
- R&D Tax Credit: Benefit from UK R&D tax credits decreased to $3.7 million in 2025 from $21.1 million in 2024, largely due to uncertainty regarding eligibility for enhanced rates under new UK regulations.
Guidance, Outlook, and Management Commentary
- Clinical Milestones:
- TRD (Treatment-Resistant Depression): The company successfully achieved primary endpoints in both pivotal Phase 3 trials (COMP005 and COMP006) in 2025/early 2026. COMP005 showed a statistically significant reduction in symptom severity (p<0.001) with a single 25mg dose. COMP006 showed significant results with two fixed doses. The company has requested a rolling submission meeting with the FDA.
- PTSD: The FDA accepted the IND application for a Phase 2b/3 trial in January 2026, enabling trial initiation.
- Commercialization: The company plans to submit a New Drug Application (NDA) for TRD in the fourth quarter of 2026 and aims to be launch-ready by the end of 2026, pending approval.
- Liquidity and Capital Resources:
- As of Dec 31, 2025, cash was $149.6 million.
- Subsequent Events (Feb 2026): The company completed an underwritten offering raising ~$140.5 million and received ~$203.2 million from the exercise of 2025 ADS Warrants.
- Runway: Management believes current cash plus proceeds from February 2026 transactions will fund operations into 2028.
- Debt: A third amendment to the Loan Agreement with Hercules Capital was executed in January 2026, providing up to $150 million in total term loans, with the first tranche of $50 million funded.
- Risks: Key risks include the need for additional capital, the uncertainty of regulatory approval (FDA/EMA/MHRA), the requirement for DEA rescheduling of psilocybin from Schedule I to allow commercial marketing, and competition from non-profit organizations (e.g., Usona Institute) and other biotech firms.
Investor Verification Checklist
- Warrant Liability Impact: Verify the non-cash nature of the $122.6 million loss in 2025 to understand the true cash burn rate versus reported net loss.
- UK R&D Tax Credit Eligibility: Confirm the status of discussions with HMRC regarding the "Research Intensive" status, as the company has not recognized potential additional credits of ~$7.3 million for 2025 due to uncertainty.
- Debt Covenants: Review the specific minimum cash covenants in the amended Hercules Loan Agreement (effective Jan 2026) and the timeline for compliance (starting Oct 1, 2027).
- Regulatory Rescheduling: Monitor the timeline for DEA rescheduling of psilocybin, which is a prerequisite for commercial sales in the U.S. and is not guaranteed.
- Subsequent Financing: Confirm the final closing details and net proceeds of the February 2026 underwritten offering and warrant exercises to validate the 2028 cash runway estimate.